ASPC

The ASPC is a group of physicians, researchers, and allied health professionals working in the field of preventive cardiology.

[Akinchan Bhardwaj, MD, DM, FACC @CathWhisperer]

@SCAI SHOCK 2026:
‼️What’s new? ‼️

The central message is:
Stage the patient, not the blood pressure, device or treatment.

Here are the key updates 🧵

@SrihariNaiduMD @SarasVallabhMD @mmamas1973 @ASPCardio

[Evangelos K. Oikonomou @ekoikonomou]

Huge congratulations to ⭐️ @TradIMYale residents @Maryam_SaniMD and @aknabdMD on co-leading 2 #AHA26 #simpubs published in @AJPCardio! 🎉

Outstanding work advancing our understanding of #AI biomarkers, #HF risk, and lifelong #CKM burden.

So proud of their achievements! 👏

[Rakendu Jayasree Rajendran @RakenduJR]

Good science, even better reunions! 🫀
#ScientficSessions2026 #AHA26
@NatTgAlliance @ASPCardio @Toluhwalase @AHAScience

[Léonie Dupuis, MD @LeonieDupuisMD]

🫀 A giant of cardiology whose discoveries shaped modern cardiovascular medicine.

#AHA26 honored the extraordinary life and legacy of Dr. Eugene Braunwald—a pioneer, mentor, and visionary whose impact will be felt for generations.

[Léonie Dupuis, MD @LeonieDupuisMD]

Big news! AHA is creating a new journal dedicated to Food and Nutrition 🌱 #AHA26 @ASPCardio

[Léonie Dupuis, MD @LeonieDupuisMD]

It takes an average of 17 years for discoveries TJ reach patients... "The Last Mile" problem. @manesh_patelMD #AHA26 @ASPCardio

[Léonie Dupuis, MD @LeonieDupuisMD]

Time for the presidential session 🫀 #AHA26 @ASPCardio

[ASPC @ASPCardio]

📉 How Much LDL-C Lowering Matters

Knowing LDL-C improved isn’t the same as knowing you’ve lowered it enough. VESALIUS-CV measured the magnitude of reduction PCSK9 inhibition can achieve, and the results were substantial.

In the lipid sub-study, median LDL-C started at about 115 mg/dL.

📊 At 48 weeks: 45 mg/dL with evolocumab vs. 109 mg/dL with placebo
📉 55% placebo-adjusted LDL-C reduction
✅ Greater reduction, fewer events

This mirrors earlier evidence from FOURIER, where evolocumab lowered LDL-C by approximately 59%, an absolute reduction of 56 mg/dL on top of statin therapy.

The clinical lesson: don’t just ask whether LDL-C improved. Ask whether you’ve achieved enough reduction for that patient’s level of risk.

Magnitude of LDL-C reduction matters.

🎥 Watch the full breakdown in our latest reel.

Supported by an educational grant from Amgen. ASPC maintains full editorial oversight and approval of program content.

Learn more: https://t.co/lInLoOmw5G

#VESALIUSCV #PCSK9 #PreventiveCardiology #CardiovascularHealth #LDLC

[Dr. Martha Gulati ♥️🫀❤️‍🩹🇨🇦 @DrMarthaGulati]

Cleaner Air for Lower Cardiometabolic Risk

🌬️ Cleaner Air
👥 150 with prediabetes; 44% women
⚖️ HEPA vs sham filtration
📊 4wk glucose variability −7.7% (95% CI −14.0 to −1.0)
✅ Promising surrogate benefit

#AHA26 #ScientificSessions26 #CVPrev

[Léonie Dupuis, MD @LeonieDupuisMD]

@ASPCardio @AJPCardio 🔎 7,262 participants: • CARDIA: n=2,968; baseline age ~25 • MESA: n=4,294; baseline age ~61
“CKM-years” = area under the CKM stage–time curve 📈
A measure of severity × duration.

[Léonie Dupuis, MD @LeonieDupuisMD]

So inspiring to see these leaders in Research goes Red! #AHA26 @ASPCardio

[Léonie Dupuis, MD @LeonieDupuisMD]

📈 Maternal CVD is on the rise!
Real-world data from PADME show increasing preexisting CVD in pregnancy, especially among women >40.
Prevalence in this group rose from ~4% to >10% between 2001–2019.
🚨 Pregnancy-related CV risk is a growing concern.
@emilyswlau @ASPCardio #AHA26

[Marcos Gamboa @mrcsgmb84]

¿Basta con bloquear la IL-6 y suprimir la PCR para reducir eventos cardiovasculares en la enfermedad renal crónica (ERC)? Una revisión en Nefrología (2026) por analiza la inflamación en la ERC y las lecciones del ensayo fase 3 ZEUS.
@SENefrologia @SLANH_ @ASPCardio @gt_rcv @Sociedad_SEMI @RZubiranS @PerlaZambrano @FaustoHerediaDr @jlgorriz @jbroseta @JonathanNefro
@jorgericof @PepaSolerR

[Suha Soni @soni_suha]

@VietHeartPA, I am glad to meet you again! You’re a gem… just missed #DropAndGiveMe20 :/ @ASPCardio

[Dr Anastasia Mihailidou FAHA FCSANZ FESC @AnastasiaSMihai]

Another great session on women’s #HeartHealth & while missed some of it due to clash of sessions, it was a real delight to see Prof @kovacic_jason fellow 🇦🇺 on the Panel with Prof Moran @ASPCardio President & other ⭐️⭐️Panelists 👏👏

Congratulations @HeartDocSadiya & team👏

[Léonie Dupuis, MD @LeonieDupuisMD]

@ASPCardio https://t.co/RcZjL2tHj6

Now published in @NEJM

[Léonie Dupuis, MD @LeonieDupuisMD]

ZEUS showed:
-tertiles of inflammation did correlate with increased CV events
-drug did reduce inflammatory markers
-however, results (primary and secondary endpoints) were neutral
#AHA26 @ASPCardio

[Léonie Dupuis, MD @LeonieDupuisMD]

Can targeting inflammation translate to fewer CV events?

ZEUS tested ziltivekimab, an IL-6 inhibitor, in pts with ASCVD, CKD, and elevated inf.

The topline result did not demonstrate a reduction in MACE (HR 0.99). Now, Dr. Ridker dives into the results! #AHA26 @ASPCardio

[Léonie Dupuis, MD @LeonieDupuisMD]

What would a brain-healthy cardiology clinic look like? @DrMarthaGulati shares her potential framework which includes spending more time assessing cognitive function and discussing it as it relates to cardiac treatments and procedures. #AHA26 @ASPCardio

[ASPC @ASPCardio]

Learn from leading experts how to recognize Lp(a) as an inherited, independent driver of ASCVD risk and integrate guideline-recommended testing into real-world cardiovascular risk assessment. Join ASPC and Decera Clinical Education for an interactive webinar on Nov 12 and earn 1.0 CME/CE credits.

Register here: https://t.co/uazZg3Kjjb

#CardiologyEducation #CardiovascularHealth #MedicalWebinar #ASCVDRisk #LpALearning